By: Adam Feuerstein | 03/04/14 - 09:33 AM EST
No specific reason was provided for Bahcall's resignation and a company spokesperson wouldn't elaborate. The subpar performance of Synta's stock price during a raging biotech bull market couldn't have helped his case for continued employment. No one but Bahcall really believed in the future of Synta's lead lung cancer drug ganetespib, either.
Synta's board is still wrangling with Bahcall over his separation agreement, according to an 8-K filed Tuesday, so the entire matter sounds contentious.
The next significant corporate update should come when Synta reports 2013 financial results on March 11. Will the company continue with the ongoing phase III study of ganetespib in non-small cell lung cancer? Or, is Bahcall's resignation the first step in a major overhaul of the company?
Synta shares are down 2% to $6.02 in early Tuesday trading.
07/29/14 - 10:26 AM EDT
07/28/14 - 12:34 PM EDT
07/28/14 - 10:56 AM EDT
07/28/14 - 09:44 AM EDT
07/25/14 - 11:30 AM EDT
07/31/14 - 11:25 AM EDT
07/31/14 - 10:11 AM EDT
07/31/14 - 06:00 AM EDT
07/30/14 - 10:36 AM EDT
07/30/14 - 08:41 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.